IL230582A0 - Pharmaceutical preparations containing 4-bromo-n-imidazolidine-2-ylidine-1h-benzaimidazole-5-amine for the treatment of retinal diseases - Google Patents

Pharmaceutical preparations containing 4-bromo-n-imidazolidine-2-ylidine-1h-benzaimidazole-5-amine for the treatment of retinal diseases

Info

Publication number
IL230582A0
IL230582A0 IL230582A IL23058214A IL230582A0 IL 230582 A0 IL230582 A0 IL 230582A0 IL 230582 A IL230582 A IL 230582A IL 23058214 A IL23058214 A IL 23058214A IL 230582 A0 IL230582 A0 IL 230582A0
Authority
IL
Israel
Prior art keywords
imidazolidin
benzimidazol
ylidene
bromo
amine
Prior art date
Application number
IL230582A
Other languages
English (en)
Hebrew (he)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL230582A0 publication Critical patent/IL230582A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL230582A 2011-07-22 2014-01-22 Pharmaceutical preparations containing 4-bromo-n-imidazolidine-2-ylidine-1h-benzaimidazole-5-amine for the treatment of retinal diseases IL230582A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161510743P 2011-07-22 2011-07-22
US201161510536P 2011-07-22 2011-07-22
PCT/US2012/047777 WO2013016252A1 (en) 2011-07-22 2012-07-22 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases

Publications (1)

Publication Number Publication Date
IL230582A0 true IL230582A0 (en) 2014-03-31

Family

ID=46599017

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230582A IL230582A0 (en) 2011-07-22 2014-01-22 Pharmaceutical preparations containing 4-bromo-n-imidazolidine-2-ylidine-1h-benzaimidazole-5-amine for the treatment of retinal diseases

Country Status (12)

Country Link
US (1) US20130046003A1 (cg-RX-API-DMAC10.html)
EP (1) EP2734202A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014521648A (cg-RX-API-DMAC10.html)
KR (1) KR20140097106A (cg-RX-API-DMAC10.html)
CN (1) CN103826631A (cg-RX-API-DMAC10.html)
AU (1) AU2012287062A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014001538A2 (cg-RX-API-DMAC10.html)
CA (1) CA2842756A1 (cg-RX-API-DMAC10.html)
IL (1) IL230582A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014000870A (cg-RX-API-DMAC10.html)
RU (1) RU2014106328A (cg-RX-API-DMAC10.html)
WO (1) WO2013016252A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
AU2020454040B2 (en) 2020-06-19 2025-03-06 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
MX2012008516A (es) * 2010-01-21 2012-10-15 Allergan Inc Agonista alfa-2 adrenergico que tiene larga duracion de efecto de baja presion intraocular.

Also Published As

Publication number Publication date
EP2734202A1 (en) 2014-05-28
JP2014521648A (ja) 2014-08-28
CA2842756A1 (en) 2013-01-31
CN103826631A (zh) 2014-05-28
BR112014001538A2 (pt) 2017-02-14
RU2014106328A (ru) 2015-08-27
US20130046003A1 (en) 2013-02-21
WO2013016252A1 (en) 2013-01-31
MX2014000870A (es) 2014-06-23
AU2012287062A1 (en) 2014-02-27
KR20140097106A (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
LT2892563T (lt) Farmacinės kompozicijos alzheimerio ligai gydyti
ZA201404121B (en) Compositions for the treatment of dry eye
IL229257A0 (en) Compositions and methods for treating retinal diseases
IL230830A0 (en) Cellular preparations for the treatment of degenerative diseases of the retina
IL234831B (en) Medical preparations for combined treatment
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
IL229017A0 (en) Oxidative diseases of the retina
PL2818482T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
EP2558103A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
SI2814473T1 (sl) Farmacevtske sestave za kombinirano terapijo
PL3524260T3 (pl) Kompozycje farmaceutyczne do leczenia braku apetytu
HUE052329T2 (hu) Applanációs tonométer
PL2604264T3 (pl) Kompozycja farmaceutyczna do leczenia chorób wirusowych
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
LT2717690T (lt) Oftalmologinės kompozicijos
EP2785342A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERTRIGLYCERIDEMIA OR DISEASES ASSOCIATED WITH HYPERTRIGLYCERIDEMIA
PT2704747T (pt) Colírios para tratamento de conjuntivocálase
GB201106985D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201106968D0 (en) Compounds for the treatment of clostridium difficile associated disease
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
AU2011903969A0 (en) Compositions for treating skin conditions
GB201110659D0 (en) composition for skin treatment
GB201110653D0 (en) Composition for skin treatment
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis